Results 111 to 120 of about 3,965 (158)

Beyond Conventional Coronary Aspiration: Advances in Thrombus Management. [PDF]

JACC Case Rep
Dautov R, Aria S.
europepmc   +1 more source

Two Decades of Real-World Data Reveals: Vigilance Signals of Drug-Induced Gingival Bleeding. [PDF]

Int Dent J
Wang B, Chen X, Niu D, Wang Y, Zhang Y, Li J.   +5 more
europepmc   +1 more source

Hirudins and fenestrins of the African medicinal leech Asiaticobdella fenestrata. [PDF]

Parasitol Res
Schulz L, Tolksdorf C, Rauch BH, Kvist S, Müller C.   +4 more
europepmc   +1 more source

Error in Figure.

JAMA Neurol
europepmc   +1 more source

Eptifibatide [PDF]

Reactions Weekly, 2012
Golongan penghambat GP IIb/IIIa merupakan salah satu antiplatelet tambahan yang dapat diberikan pada pasien acute coronary syndrome khususnya pada pasien yang menjalani Percutaneous Coronary Intervention (PCI) selain penggunaan aspirin dan ...
Presley, Bobby
core   +6 more sources

Unraveling the role of the homoarginine residue in antiplatelet drug eptifibatide in binding to the αIIbβ3 integrin receptor

Thrombosis Research, 2022
Eptifibatide is an αIIbβ3 inhibitor that is currently used in the clinic. More than 10 scientific communications indicate that eptifibatide has a Lys-Gly-Asp or Arg-Gly-Asp sequence, while it actually has a hArg-Gly-Asp sequence.
Magdolna Nagy, Kanin Wichapong, Tilman Hackeng   +2 more
exaly   +2 more sources

Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial. [PDF]

Journal of the American College of Cardiology, 2009
ObjectivesThe purpose of this study was to assess whether the early discontinuation of eptifibatide infusion in nonemergent percutaneous coronary intervention (PCI) is associated with a higher frequency of periprocedural ischemic myonecrosis ...
Andrew Starovoytov
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Development of eptifibatide

American Heart Journal, 1999
The primary cause of acute coronary syndromes is the development of a thrombus, a pathologic manifestation of platelet aggregation that occurs as part of the normal process of hemostasis. The discovery that the final common step in platelet aggregation, through the binding of fibrinogen to the activated platelet integrin glycoprotein (GP) IIb/IIIa, has
openaire   +2 more sources